Decreasing Heart Attack Patients' Time to Treatment in Emergency and Ambulatory Settings

Ximedica helped a startup company create two rapid, lateral-flow diagnostic platforms in tandem.


For every hour that a patient goes without treatment for a heart attack, the chance of survival decreases dramatically. Claiming one in every four deaths, heart attacks are the leading cause of death among both men and women in the United States. The rapid diagnosis and treatment of coronary thrombosis are imperative to ensuring the survival of the patient. Existing processes involve invasive diagnostic procedures performed in various care settings - and these handoffs serve to delay treatment and add to complications.


ReLIA Is a California-based diagnostics company founded by William “Bill” Rutter. Dr. Rutter was the co-founder of both Chiron and Genentech, as well as several other biotechnology and medical device companies. ReLIA’s novel, rapid immunofluorescence assay is capable of diagnosing myocardial infarction in as little as two minutes. ReLIA was looking for a dedicated development partner who could design and develop a device for use in emergency and point of care settings. ReLIA chose to work with Ximedica because they needed a local, trustworthy partner who could handle all stages of design and development in-house, reduce handoffs, and minimize risk to get the product to market faster.

Why Ximedica?

ReLIA elicited Ximedica’s in-house development expertise in:

  • Concept Generation
  • Systems Development
  • Software and Firmware Development
  • Rapid Prototyping
  • Precision Thermal Control
  • Optics and Laser Design & Integration
  • Manufacturing Process and Scale Up
  • Turn-Key Partner: Concept to Commercialization